IDH1 and astrocytoma (excluding glioblastoma): Previously, a Dutch study [24] revealed that IDH1 mutation was a good predictor of OS but not response to temozolomide after radiotherapy in patients with low-grade astrocytomas, which is in agreement with our findings.